Treatment of borderline personality disorder is multimodal, involving psychotherapy and prescription pharmacotherapy. Prescription drug treatment involves an array of drug classes, including, but not limited to, serotonin reuptake inhibitors (SSRIs), anxiolytics/benzodiazepines, mood stabilizers, and atypical antipsychotics. Although the borderline personality disorder drug market is extensively genericized, the range of symptoms experienced by patients with borderline personality disorder, together with patients’ heterogeneous responses to treatment, has yielded a complex treatment algorithm in which even brand-only therapies may be used, albeit often as later-line therapies. In this report, we use national patient-level claims data to explore the use of key therapies for borderline personality disorder in both newly diagnosed and recently treated patients.
- What patient share do key therapies and brands garner by line of therapy in newly diagnosed borderline personality disorder patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed borderline personality disorder patients?
- How have antidepressants, anxiolytics/benzodiazepines, and atypical antipsychotics been integrated into the treatment algorithm?
- What proportion of borderline personality disorder patients receive drug therapy within two years of diagnosis and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?
- What percentage of borderline personality disorder patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
- What are the product-level compliance and persistency rates among drug-treated patients with borderline personality disorder?
Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand use across different lines of therapy using real-world patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing their brand share.
Markets covered: United States
Real-world data: Longitudinal patient-level claims data analysis
Key companies: Allergan, Janssen, Sunovion
Key drugs: Invega Trinza, Latuda, Viibryd, aripiprazole, bupropion, escitalopram, anxiolytics/benzodiazepines, antiepileptic drugs, sertraline
Key analysis provided:
- Brand use across longitudinal patient sample.
- Newly diagnosed patient analysis.
- Treatment initiation and progression.
- Line of therapy analysis.
- Combination therapy analysis.
- Source of business for recently treated patients.
- Persistency and compliance analysis.
- Product-level patient flowcharts.
- Borderline Personality Disorder - Current Treatment - Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)
- Treatment Algorithms - Claims Data Analysis - Borderline Personality Disorder US Analysis [May 2018]
Author(s): Bethany A. Kiernan, PhD
Bethany A. Kiernan, Ph.D., is a senior director in the central nervous system/ophthalmology disorders unit of Decision Resources Group. While at Decision Resources Group, Dr. Kiernan has covered the market dynamics of numerous indications, including schizophrenia, depression, migraine, multiple sclerosis, epilepsy, and other disorders.
Dr. Kiernan’s previous experience includes eight years of scientific research conducted at Tufts University School of Medicine, Case Western Reserve University, and the College of the Holy Cross. Dr. Kiernan earned her Ph.D. degree from Case Western Reserve University.